Novo Nordisk has enjoyed a stellar stock run since launching Wegovy in 2021, but shares have retreated after it forecast much slower sales growth for 2025.
Why it matters: The GLP-1 market faces an inflection point, and Novo's deals Tuesday offer insight on how telehealth factors into its plans.
